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Summary Study objectives: to investigate the presence of sleep breathing disorders
in patients with idiopathic Parkinson’s disease (PD) and their correlation with the
severity of the disease.
Participants: Fifteen patients (mean age 6374 years) with idiopathic PD (Group A)
and 15 healthy matched controls (Group B) were studied. All patients were under
treatment with L-Dopa/Carbidopa and classified according to the UPDRS motor scale: 8
had mild disease (UPDRSo12), 6 moderate (UPDRS: 12–22) and 1 severe (UPDRS422).
Measurements and results: All participants underwent full night polysomnography
(PSG). The sleep-wake history was assessed. Spirometry, maximal respiratory
pressures and arterial blood gases were also measured. Snoring was more common
in Group A patients (73.3% vs. 33.3%, p ¼ 0:002). Among the parameters studied apnea
hypopnea index (AHI), mean O2 saturation, minimum O2 saturation, REM% sleep and
Arousal Index (Arousal Index) were statistically different between the two groups.
Furthermore, 9 PD patients fulfilled the criteria for obstructive sleep apnea-hypopnea
syndrome (OSAHS) predominately mild, 1 for central sleep apnea hypopnea syndrome
(CSAHS) and 5 were normal. In all patients a marked reduction in percentage REM
sleep was observed. Among the patients with OSAHS 5 had mild PD, 3 moderate and 1
severe. The patient with CSAHS had moderate disease. Finally, 3 patients with mild
and 2 with moderate PD had no evidence of sleep breathing disorders. Correlations
between severity of disease and sleep parameters are provided.
Conclusion: Our results suggest that sleep breathing disorders, predominantly
obstructive, seem to be common in PD and those events correlate with the severity of
the disease.
r 2003 Published by Elsevier Ltd.
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Introduction
Parkinson’s disease (PD) is a degenerative neurolo-
gical disorder characterized by akinesia, bradyki-
nesia, rigidity, postural instability and tremor.1
Sleep disorders are common in idiopathic PD, being
reported in 74–98% of patients, adversely affecting
their quality of life.2–3 The most frequent sleep
disorder in PD is sleep fragmentation with frequent
and prolonged awakenings and excessive daytime
sleepiness.4–5 Nocturia, difficulty in turning over in
bed, tremor, leg cramps, vivid dreams/nightmares,
rapid eye movement behavior disorder, back pain,
limb/facial dystonia and leg jerks are common
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problems causing nocturnal awakenings in PD
patients.6–13 There is also evidence that patients
with PD die more frequently in the early hours of
the day from respiratory ‘‘insufficiency’’ compared
to patients with other neurological disorders,
probably due to centrally medicated respiratory
problems and upper airway obstruction caused by
irregular glottic and supraglottic structures.14
There are few reports on breathing disorders
during sleep in patients with idiopathic PD who
present paroxysmal tachypnea, breath holding,
irregular breathing and sleep apnea, whereas in a
study in two patients with idiopathic PD no
breathing disorders were revealed.7,14–17 There is
one study in 10 patients with idiopathic PD (40%
untreated) which included a patient exhibiting
obstructive sleep apnea hypopnea syndrome
(OSAHS).15 Furthermore, in another study in 54
patients with idiopathic PD, all levodopa treated,
referred for excessive daytime sleepiness (EDS),
20% presented a moderate to severe OSAHS.18
The aim of this study was to assess the presence of
sleep breathing disorders in patients with idiopathic
PD under treatment and to examine if these
disorders correlate with the severity of the disease.
Methods
Fifteen patients (12 males, 3 females) suffering
from idiopathic PD diagnosed according to clinical
manifestations were recruited (Group A). All
patients presented tremor, bradykinesia and rigid-
ity and had a distinct improvement after the
administration of antiparkinsonian therapy. Pa-
tients were recruited consecutively among those
who attended the Neurological Department of the
Hospital and no one declined participation. Addi-
tionally, 15 healthy controls matched regarding
sex, age, smoking history and BMI with the Group A
consisted the control group (Group B). The control
group consisted of healthy participants randomly
chosen who did not report any sleep complaints.
The demographic characteristics of both groups,
smoking history, BMI and severity of Parkinson’s
disease are shown in Table 1. The distribution of
the patients was not uniform, as only one patient
with severe PD participated to the study. All PD
patients were under treatment with carbidopa/
levodopa individualized doses. The severity of
Parkinson’s disease was classified according to the
unified Parkinson’s disease rating scale (UP-
DRS)Fmotor scale evaluating the following para-
meters related to motor activity: speech, facial
expression, tremor at rest, action or postural
tremor of hands, rigidity, finger taps, movements
showing reduction in amplitude, rapid altering
movements of hands, legs agility, arising from the
chair, posture, gait, postural stability and body
bradykinesia and hypokinesia (Table 1).20 Exclusion
criteria for all participants were: history of lung
disease that might have led to structural or
functional pulmonary dysfunction, obesity, heart
diseases, other neurological diseases and endocri-
nological disorders. All participants underwent
physical examination and a medical history was
taken. In addition spirometry was performed and
arterial blood gases and maximum inspiratory (MIP)
and expiratory (MEP) pressures were measured.
Maximum inspiratory and expiratory mouth pres-
sures (MIP and MEP) were measured at FRC and TLC,
respectively, during maximum efforts against a
closed airway using a respiratory muscle pressure
meter (Forth Institute Structure ad Laser). The best
of three maneuvers sustained for at least 1 s was
selected for analysis. Reference values for MIP and
MEP were taken from Black and Hyatt.21 Spirometry
and flow-volume loop were recorded using a Jaeger
flowmeter (Wuerzburg, Germany), forced vital
capacity(FVC) and forced expiratory volume
(FEV1) in 1 s were measured according to standard
methods.22 Both spirometry and maximum pres-
sures were performed one hour after the adminis-
tration of the individualized dose of L-Dopa/
Carbidopa (peak dose according to the pharmaco-
kinetics of the drug).23
Participants underwent a full night polysomno-
graphy (PSG) in the sleep laboratory. Monitoring
started at 10:30 pm and ended at 06:30 am.
Recordings were made with an Alice-4 18 channel
polygraph (Alice-4 Respironics, Pittsburgh, Pennsyl-
vania, USA) and included monitoring of electro-
encephalogram (C3/A2, C4/A1 and CZ/OZ),
electrooculogram, genioglossus and anterior tibialis
electromyograms, oxygen saturation, nasal ther-
mistors and nasal canula pressure transducer,
thoracic and abdominal bands, microphone for
snoring and body position electrode (all according
to the 10–20 international electrode placement
system).24
Sleep staging was scored visually according to the
criteria of Rechtschaffen and Kales24 and micro-
arousals were defined according to the criteria of
Bonnete et al.25 Respiratory events analysis and
apnea hypopnea index was scored visually and
calculated according to international criteria with
hypopnea manifesting as an adverse of thoracoab-
dominal effort of at least 50% with an associated
oxygen desaturation of at least 4% and apnea as a
cessation of airflow at the nose and mouth lasting
at least 10 s and were classified as obstructive or
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central on the basis of the presence of paradoxical
movements of the rib cage of the abdomen.26
OSAHS was defined as mild, moderate or severe
when AHI was between 5.1 and 15, 15.1 and 30, and
greater than 30 respectively.
All participants signed a consent form approved
by the Crete University Ethics Committee.
Statistical analysis
SPSS 10.0 package for windows was used for
statistical analysis. Since the distribution of values
of sleep and respiratory parameters of subjects of
both groups were not normal we used the Mann–
Whitney test for comparison of differences be-
tween the two groups. Values are shown as mean
and median. A p-value less than 0.05 was con-
sidered as significant. In order to explore the
correlation between severity of PD (UPDRS) with
AHI, AI and median SatO2 in PD patients (group B)
we performed a logarithmic (log(10)) transforma-
tion of the above parameters in order to achieve a
normal distribution of values and therefore to
enable the use of parametric correlation (Pearson
and multiple regression) tests.
Results
Respiratory parameters
On average the FEV1, FVC, FEV1/FVC predicted
were within normal limits in both groups. The
median values of MIP and MEP in PD patients were
55% pred and 45% pred, respectively, while normal
controls they were 83.5% pred and 79% pred
respectively (po0:0000). MIP and MEP were not
significantly correlated to FEV1, FVC and FEV1/FVC.
The arterial blood gases were within normal limits
in all participants. Table 2 presents a summary of
the measured respiratory parameters in both
groups.
Sleep parameters
The median rapid eye movement (REM) sleep time
was 9.0% of the total duration in PD patients and
16.0% in healthy controls (p ¼ 0:005). Patients
presented frequent awakenings and the median
Arousal Index (AI) was 21.0/h, while in healthy
controls AI it was 9.9 (p ¼ 0:0002), showing that
sleep fragmentation in PD patients is almost 2.12
times higher compared to normal controls. The
median frequency of leg movements during sleep
was 5.9/h in PD patients and 3.2/h in healthy
controls (p ¼ 0:009) (Table 3).
Sleep breathing parameters
Snoring
Eleven (73.3%) of the patients were snorers. Among
healthy controls 5 (33%) were habitual snorers and
3 snored occasionally.
Apnea/hypopnea events
Five patients (33.3%) had a normal pattern of
breathing during sleep, whereas 11 (73.3%) pre-
sented some type of sleep breathing disorders
(Fig. 1). All patients who exhibited sleep breathing
disorders complained of daytime sleepiness,
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Table 1 Demographic characteristics of subjects.
Group A Group B
Total number 15 15
M/F 12/3 12/3
BMI 2771.3 2771.2
Age7SD (yrs) 6374 6074
Duration of Parkinson’s disease (yrs) 675
Smoking
history
Smokers 5 (mean pack years:
70.0721.6)
7 (mean pack years:
62.1721)
Non-smokers 7 7
Ex smokers 3 1
Disease
severity
(UPDRS)
Mild (UPDRS o12) 8
Moderate (12pUPDRSp22) 6
Severe (UPDRS422) 1
Group A: Parkinson’s disease patients.Group B: Controls.
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choking or gasping during sleep, daytime fatigue,
unrefreshing sleep and recurrent awakenings
from sleep. The Epworth Sleepiness Scale was
12.3 for the patients, while for the control
group it was 6.1 (p ¼ 0:0014). The median AHI
was 11.0 for PD patients and 5.7 for healthy
controls (p ¼ 0:048), the median O2 saturation
during sleep was 93.0% for patients and 96% for
healthy controls (p ¼ 0:0003), while the median
lowest O2 saturation was 90.0% for patients and 92%
for healthy controls (p ¼ 0:002). All measured
parameters have been adjusted to their BMI.
Among the 10 patients who exhibited sleep breath-
ing disorders, 9 fulfilled the criteria for moderate
obstructive sleep apnea hypopnea syndrome
(OSAHS) (apneas: 15.1–30 /h) and one patient
suffered from central sleep apnea hypopnea syn-
drome (CSAHS).
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Table 3 Comparison of sleep variables between groups.
Sleep parameter
Snoring (% patients)
Group A (n ¼ 15) Group B (n ¼ 15) p
73.3 33.3 0.002a
Mean Median Mean Median
TST (h) 5.9 6.0 5.8 6.2 0.8b
REM % 10.8 9.0 16.4 16.0 0.005b
AHI (NL: 0–5) 12.2 11.0 5.7 5.7 0.048b
Median SaO2 92.5 93.0 95.8 96.0 0.0003
b
Minimum SaO2 88.5 90.0 92.1 92.0 0.002
b
AI 24.1 21.0 9.9 9.9 0.0002b
Leg movements (/h) 5.4 5.9 3.3 3.2 0.009b
Group A: Parkinson’s disease patients.Group B: Controls.NL: Normal values.TST: Total sleep time, AHI: Apnea hypopnea index,
AI: Arousal index.
aChi-square test.
bMann–Whitney test.
Table 2 Comparison of respiratory parameters between groups.
Group A (n ¼ 15) Group B (n ¼ 15) pn
Mean Median Mean Median
FEV1 (% pred) 89 88.6 90.4 86.8 0.9
FVC (% pred) 93 89.5 95.6 92 0.73
FEV1 / FVC pred 94 97 95.2 95.8 0.59
MIP (% pred) 62 55 82 83.5 o0.0000
MEP(% pred) 41 45 79 79 o0.0000
PO2 (mmHg) 80 81 83 84 0.98
PCO2 (mmHg) 42 42 39 39 0.97
pH 7.4 7.4 7.4 7.4 1.0
Group A: Parkinson’s disease patients. Group B: Controls.
nMann–Whitney test.
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Figure 1 Relationship between severity of Parkinson’s
disease and sleep breathing disorders.
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Figure 1 shows the distribution of the PD patients
according to their breathing pattern during sleep
and the severity of PD. Among the patients with
OSAHS, 5 had mild PD, 3 moderate PD and 1 severe
PD. The patient with CSAHS had moderate PD.
Among the patients with no evidence of sleep
breathing disorders, 3 had mild PD and 2 moderate
PD.
In Table 4 it is shown that the logarithmically
transformed values of UPDRS correlated signifi-
cantly with the logarithmically transformed values
of AHI, AI and median SatO2. The correlation
remained significant after adjustment for age in a
multiple regression model (partial correlations and
p values are also shown in Table 4). In the same
table it is shown that there was a statistically
significant correlation between logarithmically
transformed AHI and logarithmically transformed
AI before and after adjustment for age. Results of
the sleep study and correlations between severity
of disease and sleep parameters are shown in
Tables 5 and 6, respectively.
Discussion
A number of studies have shown that the most
common sleep disorder in PD patients is difficulty of
maintaining sleep, as a result of sleep fragmenta-
tion.6–8,10,11,16,27–29 Sleep fragmentation is also
common in age-matched control groups but PD
patients wake up more frequently suggesting that
the disease itself plays a more important role than
age. Furthermore frequent awakenings appear to
be related to the disease process.6,8,14,18 The
results of this study showing frequent awakenings
in PD patients with an AI approximately high are in
agreement with previous reports.6–8,10,11,16,18,27–30
Frequent nocturia, nocturnal akinesia and other
kinetic dysfunctions as dystonias, cramps, pains,6–8
increased muscle activity,31 depression10 and de-
clining efficacy of dopaminergic agents27 have been
reported as causes for the sleep fragmentation in
PD. In the current study the significant correlation
between AHI and AI suggests that many of the
arousals are strongly associated with the high
incidence of apnea/hypopnea events whereas
kinetic dysfunctions contribute less to the sleep
fragmentation.
The TST and REM sleep are usually decreased in
PD patients. In our study TST was slightly reduced
(median TST:6.0 h) ,while in other studies TST
varies from 4.2 to 4.89 h15–16 with some reports
finding that TSTwas within the normal range.6,18–19
In this study REM sleep was reduced with median
REM (%) comprising 9.0% of the TST. This is in
agreement with previous reports showing values
ranging from 8.5% to 20%.5–6,15–17,19,28–29 Several
conditions such as depression, frequent awakenings
due to motor deficits, levodopa, dopaminergic
agonists causing hallucinations, selegiline, benzo-
diazepines, amitriptiline and the first-night effect
of the sleep study have been suggested as causes of
the reduction of REM% and TST.5–6,16,29
The main finding of our study was the high
incidence of apneic syndromes that were detected
in patients with PD. To our knowledge, only isolated
cases of obstructive and central sleep apneas have
been previously reported in PD patients without
fulfilling the criteria of sleep apnea syn-
dromes.7,11,19 Two studies suggested a high inci-
dence of mainly obstructive and few central apneic
episodes: the first one presents one patient (5%)
with OSAHS in 20 idiopathic and postencephalitic
PD patients15 and the second one found that 20% of
54 PD patients who were referred due to excessive
daytime sleepiness (EDS) had AHI greater than 15/h
indicating OSAHS.18 In previous studies it has been
found that some patients with idiopathic PD and
parkinsonism presented upper airway obstructio-
n(UAO) and abnormal flow/volume loops, which
may be related to the high incidence of apnea/
hypopnea events that were detected in the current
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Table 4 Correlations between logarithmically transformed sleep parameters in univariate (Pearson’s) and
multiple regression (after adjustment for age) models.
Univariate correlation Multiple regression after adjustment for age
r p Partial correlation p
LogUPDRS vs. LogAHI 0.67 0.005 0.68 0.01
LogUPDRS vs. LogAI 0.58 0.02 0.53 0.04
LogUPDRS vs. Logmedian O2 Sat 0.66 0.007 0.63 0.01
LogAHI vs. LogAI 0.83 0.001 0.79 0.0007
LogUPDRS: Logarithmically transformed values of Unified Parkinson’s disease Rating Scale.LogAHI: Logarithmically transformed
values of Apnea Hypopnea Index.LogAI: Logarithmically transformed values of Arousal Index.Logmedian O2 sat: Logarithmically
transformed values of median O2 saturation.
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study.15,18,31–32 Although in the current study, due
to exclusion of subjects with anatomical and
functional pulmonary diseases, pulmonary function
tests were close to normal in both groups, in spite
the fact that there was a considerable proportion
of smokers among the recruited subjects a severe
reduction of MIP and MEP was found suggesting
abnormalities of respiratory muscle function. This
corroborates previous studies showing evidence of
muscular dysfunction at the level of the glottic and
supraglottic structures with irregular jerky move-
ments during endoscopic evaluation.14–15,33–34 Ad-
ditionally, in our study there was a significant
correlation between the severity of PD and the
severity of sleep breathing disorder. Sleep breath-
ing disorders expressed by AHI and clinical symp-
toms are correlated to the severity of PD evaluated
by the UPDRS. Patients with mild PD present either
none or mild OSAHS, whereas patients with
moderate to severe PD suffer from more severe
OSAHS with higher AHI and more serious clinical
symptoms. This is in agreement with a previous
study relating the incidence of apneic episodes
with the severity of the disease.15
In conclusion, our results suggest that patients
with idiopathic PD seem to exhibit a high incidence
of sleep breathing disorders, predominantly ob-
structive. In addition, a significant correlation
between the severity of the disease and the
severity of sleep breathing disorders was found.
Finally, the results of the present study suggest that
sleep studies should be performed in patients with
PD especially those presenting symptoms asso-
ciated with sleep, in order to verify the presence
of sleep breathing disorders.
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